Evidence map›Paper›PMID 32645104›Full record

ArticlePloS one2020

Guided screen for synergistic three-drug combinations.

Melike Cokol-Cakmak, Selim Cetiner, Nurdan Erdem, Feray Bakan, Murat Cokol

Abstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Oxphos targeting ofFrontiers in oncology · 2025
    Article
  3. Article
  4. Hybrid peptides as platform for synchronized combination therapy.Colloids and surfaces. B, Biointerfaces · 2023
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Melike Cokol-CakmakFaculty of Engineering and Natural Sciences, Sabanci University, Istanbul, Turkey.
Selim CetinerFaculty of Engineering and Natural Sciences, Sabanci University, Istanbul, Turkey.
Nurdan ErdemFaculty of Engineering and Natural Sciences, Sabanci University, Istanbul, Turkey.
Feray BakanNanotechnology Research and Application Center, Sabanci University, Istanbul, Turkey.
Murat CokolFaculty of Engineering and Natural Sciences, Sabanci University, Istanbul, Turkey.ORCID 0000-0001-9084-3367

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combinations of three or more drugs are routinely used in various medical fields such as clinical oncology and infectious diseases to prevent resistance or to achieve synergistic therapeutic benefits. The very large number of possible high-order drug combinations presents a formidable challenge for discovering synergistic drug combinations. Here, we establish a guided screen to discover synergistic three-drug combinations. Using traditional checkerboard and recently developed diagonal methods, we experimentally measured all pairwise interactions among eight compounds in Erwinia amylovora, the causative agent of fire blight. Showing that synergy measurements of these two methods agree, we predicted synergy/antagonism scores for all possible three-drug combinations by averaging the synergy scores of pairwise interactions. We validated these predictions by experimentally measuring 35 three-drug interactions. Therefore, our guided screen for discovering three-drug synergies is (i) experimental screen of all pairwise interactions using diagonal method, (ii) averaging pairwise scores among components to predict three-drug interaction scores, (iii) experimental testing of top predictions. In our study, this strategy resulted in a five-fold reduction in screen size to find the most synergistic three-drug combinations.

Indexed as

Drug SynergismAminoglycosidesAnti-Bacterial AgentsCopper SulfateDrug InteractionsErwinia amylovoraGentamicinsMicrobial Sensitivity TestsAminoglycosidesAnti-Bacterial AgentsCopper SulfateGentamicinskasugamycin

Identifiers

PMID32645104
PMCPMC7347197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.